CTOs on the Move

Dova Pharmaceuticals

www.dova.com

 
Dova is a clinical-stage pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet medical need. With a nimble approach and a team of bright minds aglow with passion, we’re...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.dova.com
  • 240, Leigh Farm Road
    Durham, NC USA 27707
  • Phone: 844.506.3682

Executives

Name Title Contact Details

Similar Companies

Pervasis Therapeutics Inc

Pervasis Therapeutics Inc is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tris Pharma

Tris Pharma, Inc. is one of the top five privately-owned specialty pharmaceutical companies in the U.S. with a focus on the development of pharmaceutical science and technology-based products. Specifically, we are engaged in research, development, manufacturing, and commercialization of both branded products and specialty generic products. We have more than a dozen solid and liquid products in the U.S. market based on our numerous NDAs and ANDAs and a rich and growing portfolio of more than 30 U.S. granted patents. Our commercialization success is driven by internal resources for our pediatric products and by licensing of our non-pediatric products to other companies. Our mission is to understand the science of developing drug products with unique attributes, bring to market products that add value to our patients and customers, and provide a benefit to our company, employees and society at large.

Humanetics

Humanetics Corp. is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

i-novel Medical

i-novel Medical is a Culver City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aldeyra Therapeutics, Inc

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.